Anzu’s April Newsletter features BioSkryb, sharing their latest collaborations with Ultima Genomics and Tecan Group —plus key milestones from our portfolio companies!
I’m Kalyn Schieffer, I lead Public Relations efforts for Anzu Partners and many of our portfolio companies. My primary objective is to ensure that the firm and, more importantly, our portfolio companies are getting in front of the right audiences and working with media to highlight companies’ key milestones. Thus far in 2025, our team has produced over more than one press release a week (a 40% increase over last year) and has earned over 50 pieces of coverage for our portfolio companies, including in Axios and The Atlantic.
This month, we were particularly excited to see strong momentum around BioSkryb Genomics, as they announced several new commercial collaborations. Their new grant program with Ultima Genomicsaims to advance research in emerging areas of oncology—fields that have long been hamstrung by a lack of technologies to address critical research questions and by the high costs associated with sequencing. Additionally, BioSkryb’s new collaborative single-cell multiomics workflow withTecan Group generated coverage in Genome Web, GEN, LabCompare, Scientist Live, and more.
If you are interested in keeping up with Anzu portfolio media coverage throughout the month, our team updates thenewsroomon the Anzu website in real time.
Thank you for your continued support.
Sincerely,
Kalyn Schieffer
PORTFOLIO COMPANY UPDATES
BioSkryb Genomics Launched Collaborations with Ultima Genomics and Tecan Group
BioSkryb Genomics, a pioneer in single-cell and ultra–low-input multi-omic solutions, announced a collaboration with Ultima Genomics, a leader in scalable and cost-effective sequencing. As part of the collaboration, the companies launched a grant program to advance research in important emerging areas of oncology that have been hampered by a lack of technologies to address critical research questions and by the high costs associated with sequencing. All cancer researchers are encouraged to apply for this newly launched joint grant program, which offers awards providing comprehensive multi-omic studies worth up to 2,000 single cell genomes at no cost. The news was covered by Genome Web.
BioSkryb also announced a high-throughput single-cell workflow with Tecan Group (SIX Swiss Exchange: TECN). The workflow combines BioSkryb’s 384-well format of the ResolveOME™ Whole Genome and Transcriptome Single-Cell Core Kit with the Uno Single Cell Dispenser™ by Tecan.
The integrated solution enables parallel high-resolution analysis of hundreds to thousands of individual cells, addressing growing demand for scalable, multiomics approaches in single-cell research. By reducing reliance on time consuming cell sorting techniques, such as fluorescence-activated cell sorting (FACS), the workflow offers a more streamlined and accessible approach to comprehensive genomic and transcriptomic profiling.
EnCharge AI Appointed Key Finance and HR Executives Following $100M Series B
EnCharge AI, the company pioneering scalable analog in-memory AI accelerators to power AI inference from edge to cloud, appointed Jason Huang as Vice President of Finance and Leslie Szeto as Director of Human Resources. These key hires support EnCharge’s next chapter of growth following its recent $100M Series B funding round, and complement last month’s appointment of Dr. Shwetank Kumar as Chief Scientist.
In their new roles, Huang will optimize EnCharge’s financial strategy to accelerate commercial growth and market expansion, while Szeto will drive talent acquisition and organizational development aimed at establishing a high performing and global workforce.
CytoTronics Launched a Neural Application for Pixel
CytoTronics, a pioneer of semiconductor-based platforms for discovery in cell biology, launched a pioneering innovation for neurodegenerative disease and neurotoxicity research, which enables high-throughput screening for drug discovery at unprecedented scale.
With the Neural application on Pixel, electrical imaging and electrophysiological data are captured on the same cells at the same time in a single, multiplexed assay—presenting a complete picture of cell health, structure, and electrical activity.
CytoTronics has active collaborations with key cell, organoid, and spheroid providers requiring the sophisticated cell characterization that Pixel enables. Anatomic, Axol Bioscience,BrainXell, Trailhead Biosystems and others are putting the system to use for applications in Parkinson’s and Alzheimer’s disease, ALS, blood-brain barrier/CNS function, and pain research. The company has over 40 Pixel collaborator sites across seven countries in both industry and academia.
Codetta Bio, a leader in multi-omics innovation, launched its Concerto™ System, a revolutionary new multi-omics platform, at the American Association for Cancer Research (AACR) Annual Meeting 2025. Concerto is the first platform to enable simultaneous, quantitative measurement of proteins, DNA, and RNA from a single sample. Its launch at AACR marks a major milestone in the evolution of multi-omics technologies and their impact on oncology, immunology, and precision medicine. Codetta also recently closed a strategic investment by a major global diagnostic company.
To celebrate the launch, Codetta invited researchers to be a part of “The Opening Concerto”—an exclusive early access program for the first 50 organizations or individuals who signed up during AACR. This group will play a leading role in bringing Codetta’s new multi-omics era to life.
XGS Energy’s COO, Ghazal Izadi, Ph.D., officially launched the company’s first episode of The Power Shift Podcast, where she will be sitting down with leaders across the energy space to explore the innovations shaping our clean energy future.
For the first episode, Ghazal sat down with Josh Prueher, CEO of XGS Energy. They dove into why geothermal’s moment is now, what it truly takes to deliver 24/7 clean power, and how XGS is working to unlock geothermal’s full potential—at scale.
Xendee co-founders Adib Nasle and Michael Stadler joined the Latitude Mediapodcastto discuss future proofing data center power infrastructure. Adib Nasle also joined the SunCast Media podcast to discuss Xendee’s technology.
EnCharge AI was mentioned in a Mobility Engineering Tech piece on startups developing AI for defense applications.
AM Batteries CEO Lie Shi was quoted in aBattery Power Online piece on EV battery industry outlook. AMB’s Chief Manufacturing Officer Hieu Duong was featured in an EV Engineering piece where he also spotlighted South 8 Technologies. AM Batteries was also spotlighted bySupply Chain Brain.
South 8 Technologies was included in a list of 50 hard tech companies in San Diego by Fresh Brewed Tech.
Zeteo Tech’s BreathBiomicstechnology was featured in aDrug Discovery News Piece ondetecting tuberculosis in human breath.
Anzu Partners and our portfolio companies are growing, and we’re always looking for exceptional talent. Whether you're seeking new career opportunities or exploring ways to collaborate, we invite you to connect with us and become part of our network.
To stay up to date on the latest news from both Anzu and our portfolio companies, follow us on social media.
ABOUT ANZU PARTNERS
Anzu Partners is an investment firm that focuses on industrial and life science technology companies with the potential to transform their industries. Anzu works with entrepreneurs to develop and commercialize technological innovations by providing capital alongside deep expertise in business development, market positioning, intellectual property, global connectivity, and operations. For more information, please visit https://anzupartners. com/.
The information contained in this newsletter is being provided by Anzu Partners for informational purposes only. The information was obtained from various sources, but Anzu Partners cannot assure its accuracy. This is neither an offer to sell nor a solicitation for an offer to buy an interest in any fund managed by Anzu Partners. Any such offer or solicitation will only be made to qualified potential investors pursuant to a private placement memorandum. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.
You are receiving this email because you requested to be added to Anzu Partners' monthly newsletter distribution list.
